International Journal of Drug Delivery Technology
Volume 15, Issue 3

siRNA Drug Delivery for Cystic Fibrosis: A Review 

Asmita Bhargawe*, Surendra Agrawal

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (DU), Sawangi Meghe, Wardha, Maharashtra, India 

Received: 13th Jun, 2025; Revised: 21st Aug, 2025; Accepted: 31st Aug, 2025; Available Online: 25th Sep, 2025 

ABSTRACT

Cystic Fibrosis (CF) is a genetic condition that impacts life expectancy, caused by mutations in CFTR gene, which interferes with ion transport across epithelial membranes. This condition primes to manufacture of thick, dehydrated mucus that can block airways &ducts, especially in the lungs &pancreas, resulting in ongoing infections and gradual tissue harm. Even with the progress made in pharmaceutical treatments like CFTR modulators, finding a definitive cure continues to be a challenge. Nonetheless, the clinical promise of siRNA faces obstacles such as swift degradation by nucleases, inadequate membrane permeability, restricted mucus penetration, and challenges in effective intracellular delivery. Improved delivery methods are essential to protect siRNA and ensure accurate targeting to the areas in need. This review discoversprobable of siRNA-based DDS in treatment of cystic fibrosis, highlighting the role of non-viral carriers like lipid-based nanoparticles, cationic polymers, dendrimers&peptide-mediated vectors. There is a strong focus on bio-inspired methodologies, including exosomes and mucus-penetrating particles. Special attention is given to tackling the unique challenges posed by cystic fibrosis, including changes in mucus composition and the presence of inflammation. Recent advancements in preclinical research, innovative inhalation formulations, and initial findings from clinical trials are examined to offer a comprehensive understanding of the current developments. The research also explores how siRNA therapies can be combined with existing CFTR modulators to enhance their effectiveness. Ultimately, it explores future paths focused on personalized delivery methods, cutting-edge nanotechnology, and navigating regulatory challenges. Continuous progress in siRNA delivery presents a promising opportunity for a transformative therapy that could change the course of cystic fibrosis.

Keywords: Gene silencing, nanocarriers, hindrances, paradigmatic, exosomes, pathophysiological.

How to cite this article: Asmita Bhargawe, Surendra Agrawal. siRNA Drug Delivery for Cystic Fibrosis: A Review. International Journal of Drug Delivery Technology. 2025;15(3):1383-94. doi: 10.25258/ijddt.15.3.61

REFERENCES

  1. Gagliardo C, Saiman L. Microbiology of cystic fibrosis: epidemiology of cysti c fibrosis pathogens and clinical microbiology laboratory methods. Hodson and Geddes’ Cystic Fibrosis, CRC Press, Taylor & Francis Group, LLC. 2015 Jul 24:174-85.
  2. Lamberti G, Barba AA. Drug delivery of siRNA therapeutics. Pharmaceutics. 2020 Feb 20;12(2):178.
  3. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine: Nanotechnology, Biology and Medicine. 2009 Mar 1;5(1):8-20.
  4. Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, Aljabali AA, Awidi A. siRNA: Mechanism of action, challenges, and therapeutic approaches. European journal of pharmacology. 2021 Aug 15;905:174178.
  5. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiology and molecular biology reviews. 2003 Dec;67(4):657-85.
  6. MacRae IJ, Zhou K, Doudna JA. Structural determinants of RNA recognition and cleavage by Dicer. Nature structural & molecular biology. 2007 Oct;14(10):934-40.
  7. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005 Nov 18;123(4):607-20.
  8. Pund S, Chandak R, Rajurkar V, Kharat N, Khalil SS, Shaikh S, Parve K, Kadam M, Choudante S, Pulate C, Wakale V. A review on nanomedicines in treatment of thyroid and their applications in management of thyroid disorders. International journal of health sciences. 2022;6(S5):11141-54.
  9. Blanchard A, O'Callaghan MW, Neufeld EJ. RNA interference therapeutics in the treatment of genetic diseases. Mol Genet Metab. 2021;132(3):133-45.
  10. Kouzarides T. Chromatin modifications and their function. 2007;128(4):693-705.
  11. Matzke MA, Kanno T, Matzke AJ. RNA-directed DNA methylation: the evolution of a complex epigenetic pathway in flowering plants. Annu Rev Plant Biol.2015;66:243-267.
  12. Slotkin RK, Martienssen R. Transposable elements and the epigenetic regulation of the genome. Nat Rev Genet. 2007;8(4):272-285.
  13. Bardoliwala D, Patel V, Javia A, Ghosh S, Patel A, Misra A. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Therapeutic delivery. 2019 May 1;10(5):311-32.
  14. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome medicine. 2017 Dec;9:1-6.
  15. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nature materials. 2013 Nov;12(11):967-77.
  16. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides. 2009 Jun 1;19(2):89-102.
  17. Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017 Apr 5;7(4):77.
  18. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nature materials. 2013 Nov;12(11):967-77.
  19. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MØ, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Molecular Therapy. 2006 Oct 1;14(4):476-84.
  20. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nature reviews Drug discovery. 2005 Jul 1;4(7):581-93.
  21. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006 May 19;312(5776):1027-30.
  22. He Q, Zhang Z, Gao Y, Shi J, Li Y. Intracellular localization and cytotoxicity of spherical mesoporous silica nano‐and microparticles. Small. 2009 Dec 4;5(23):2722-9.
  23. Pisanic Ii TR, Zhang Y, Wang TH. Quantum dots in diagnostics and detection: principles and paradigms. Analyst. 2014;139(12):2968-81.
  24. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Advanced drug delivery reviews. 2011 Jan 1;63(1-2):24-46.
  25. Bozzuto G, Molinari A. Liposomes as nanomedical devices. International journal of nanomedicine. 2015 Feb 2:975-99.
  26. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021 Dec;6(12):1078-94.
  27. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chemical reviews. 2015 Oct 14;115(19):10938-66.
  28. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019 Oct 1;28:100766.
  29. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nature Reviews Materials. 2016 Oct 18;1(12):1-7.
  30. Wang J, Li L, Wu Y, Liu Y. Design and application of antifouling bio-coatings. Polymers. 2025 Mar 17;17(6):793.
  31. Ways TM, Lau WM, Khutoryanskiy VV. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers. 2018 Mar 5;10(3):267.
  32. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of controlled release. 2006 Aug 10;114(1):100-9.
  33. Griesenbach U, WFW Alton E. Progress in gene and cell therapy for cystic fibrosis lung disease. Current pharmaceutical design. 2012 Feb 1;18(5):642-62.
  34. Motamedi H, Ari MM, Alvandi A, Abiri R. Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review. Frontiers in Microbiology. 2024 Jun 13;15:1393646.
  35. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature biotechnology. 2011 Apr;29(4):341-5.
  36. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020 Feb 7;367(6478):eaau6977.
  37. Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proceedings of the National Academy of Sciences. 2011 Apr 19;108(16):6656-61.
  38. Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Molecular pharmaceutics. 2012 Nov 5;9(11):2961-73.
  39. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials. 2009 May 1;30(13):2591-7.
  40. Kim D, Jeong YY, Jon S. A drug-loaded aptamer− gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS nano. 2010 Jul 27;4(7):3689-96.
  41. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral research. 2008 Mar 1;77(3):225-31.
  42. McKiernan PJ, Cunningham O, Greene CM, Cryan SA. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. International journal of nanomedicine. 2013 Oct 11:3907-15.
  43. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, Kabel AC. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008 Sep 26;321(5897):1837-41.
  44. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clinical microbiology reviews. 2008 Oct;21(4):583-93.
  45. Jiang X, Wang N, Liu C, Zhuo Y, Liang L, Gan Y, Yu M. Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities. Drug Discovery Today. 2023 Apr 1;28(4):103507.
  46. Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert review of respiratory medicine. 2019 Aug 3;13(8):709-25.